(Approval lapsed) RIFADIN rifampicin 300 mg capsules, (United Kingdom)

Tuberculosis

In the initial treatment and in re-treatment of patients with tuberculosis, Rifadin must be used in conjunction with at least one other antituberculosis drug.

Leprosy

In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment.

As an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs.

Meningococcal Disease

Prophylaxis of meningococcal disease in close contacts of known cases and in carriers (Rifadin is not indicated for the treatment of meningococcal infections).

Haemophilus Influenzae

Prophylaxis of household contacts of patients with H. influenzae type B.